Emerging non-cytotoxic therapies such as IFN-gamma inhibitor (NI-0501), anti-IL-6 agents (tocilizumab), and JAK-inhibitors (ruxolitinib), either as single agents or in combination with traditional HLH therapies, hold promise for the therapy of M-HLH in adults. Here, IFNG is linked to hemophagocytic syndrome.